Skip to main content
OpenTrials
Recruiting

NCT Number: NCT07377357

Immediate and 1-week Efficacy of a Single Session of Sciatic Nerve Electrical Stimulation in the Management of Low-back Related Leg Pain

This clinical study focuses on people who experience long-term low-back related leg pain (commonly called sciatica). This type of pain is often associated with nerve irritation or compression in the lower spine and can cause symptoms like shooting or burning pain, tingling, numbness, or weakness in the leg. Many patients continue to suffer from this problem for months or years, and available treatments (including painkillers, anti-inflammatory drugs, or even surgery) do not always provide lasting relief. Because of this, there is a strong need to explore safe, non-drug, non-surgical therapies. The purpose of this study is to test the immediate and short-term efficacy and safety of a single session of a treatment called Percutaneous Electrical Nerve Stimulation (PENS) when applied near the sciatic nerve, the large nerve that runs from the lower back through the buttock and down the leg. PENS uses very thin sterile needles inserted under ultrasound guidance next to the nerve. A gentle electrical current is then applied for about 30 minutes to stimulate the nerve in a controlled way. This may help calm down nerve sensitivity, reduce inflammation, and decrease pain. The investigators will compare PENS with three other options: Transcutaneous Electrical Nerve Stimulation (TENS): A commonly used therapy where mild electrical stimulation is applied through adhesive patches placed on the skin; Dry needling without electrical current: Thin needles are inserted under ultrasound guidance but no current is applied; and placebo treatment: A simulated version of the therapy with no active current, designed to look and feel similar so that participants do not know which treatment they are receiving. The study is designed as a randomized, controlled, double-blind trial, which means that participants are assigned to one of the four groups by chance (like flipping a coin), and neither the patients nor the therapists who collect the measurements will know which treatment has been given. This design ensures fairness and reliability of the results. The investigators will measure: Back and leg pain levels, using a simple 0-10 scale; Disability, meaning how much the pain limits daily activities, measured with a well-known questionnaire; Quality of life, both physical and mental health aspects; Nerve-related pain features, like burning or electric-like sensations; Flexibility and movement, through the Straight Leg Raise test; Sensitivity to pressure and nerve stiffness, using ultrasound elastography, which is a safe imaging technique; and patients' global impression of improvement and any side effects. Assessments will take place before and immediately after the treatment session and after 1 week, allowing the investigators to see both the immediate and short-term effects. Safety considerations: Previous research shows that PENS and similar techniques are generally very safe. The most common side effects are mild and short-lasting, including temporary soreness, heaviness in the leg, or a small bruise. Serious complications are extremely rare. To minimize risks, all procedures will be carried out by experienced physiotherapists, using real-time ultrasound to guide needle placement and ensure accuracy. Only sterile, single-use needles are employed. By comparing PENS, TENS, dry needling, and placebo, this study seeks to determine whether a single session of PENS provides superior benefits in reducing pain, improving function, and enhancing quality of life for patients with sciatica-type low back pain. If successful, this treatment could become a valuable alternative to drugs or surgery, offering patients a safe and effective therapy to better manage their condition and regain daily function.

Recruiting

Interested in participating?

Request Info

Key information

Age range

18 year–70 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

Hospital Universitario 12 de Octubre

Madrid, 28041, Spain

Location status: Recruiting

Location contact

Gabriel R Rabanal-Rodríguez

CONTACT

[email protected]

0034 91 394 15 24

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Neuropathic-like LBRLP (sciatica).
  • S-LANSS score ≥ 12 points.
  • LBRLP lasting more than 6 months.
  • Age between 18 and 70 years.
  • LBRLP in the past 4 weeks has been severe enough to limit usual activities or change daily routines for more than 1 day.
  • At least one period of 6 months to 1 year during which the participant did not go a full month without LBRLP.
  • LBRLP intensity of at least 3/10 on the NPRS.
  • Ability to provide informed consent.

Exclusion criteria

  • Acute injury or recent major trauma history.
  • Relevant painful conditions of the hip joint or pelvic/sacroiliac region.
  • Symptoms compatible with cauda equina syndrome (loss of bladder/bowel control, sexual dysfunction, paralysis of lower limbs, etc.).
  • Previous surgery on the spine, pelvis or hip.
  • Prior treatment with anesthetic or anti-inflammatory blocks or with radiofrequency (facet, sacroiliac, radicular, epidural, etc.) in the past two years.
  • Any neurological or systemic disease that could limit participation in the study.
  • Inability to communicate in Spanish or understand study instructions and content.
  • General contraindications for invasive physiotherapy and electrotherapy techniques.

Treatment and study plan

Percutaneous Electrical Nerve Stimulation

Procedure

Participants will receive real ultrasound-guided dry needle insertion (0.30 mm × 60 mm and 0.30 mm ×50 mm) to the perineural region adjacent to the sciatic nerve at both the subgluteal fold and the posterior thigh (junction between the middle and distal thirds). Electrical stimulation will be applied using the Endomed 484® electrotherapy unit (PRIM Physio, Madrid, Spain) in continuous biphasic mode at low frequency (2 Hz), 250 μs pulse width for 30 minutes. Intensity will be adjusted to elicit a visible, mild muscle contraction.

Other names: PENS

Placebo Transcutaneous Electrical Nerve Stimulation

Procedure

Adhesive electrodes will be placed near the intervention site (sciatic nerve between the subgluteal fold and the distal third of the thigh) but connected to a disabled channel to simulate placebo TENS.

Other names: Placebo TENS

Transcutaneous Electrical Nerve Stimulation

Procedure

Participants will receive real superficial electrical stimulation via adhesive electrodes connected to the Endomed 484® unit, configured for TENS (non-invasive). Parameters will include continuous biphasic current, 2 Hz, 250 μs, 30 min, producing a clear sensory perception and mild muscle contraction.

Other names: TENS

Placebo Percutaneous Electrical Nerve Stimulation

Procedure

A sham ultrasound-guided dry needling procedure will be performed using Streitberger placebo needles, which contact the skin superficially without penetration. Cables for PENS will be placed on the skin but connected to a disabled channel to simulate placebo PENS.

Other names: Placebo PENS

Real Dry Needling (without Percutaneous Electrical Nerve Stimulation)

Procedure

Participants will receive real ultrasound-guided dry needling but without electrical stimulation. The needles will remain in place for 30 minutes, with the PENS channel disabled to act as placebo.

Other names: Real Dry Needling (without PENS)

Primary outcomes

  1. Pain intensity

    Time frame: Baseline, immediately after the intervention and 1 week post-intervention.

    Pain intensity will be assessed using the NPRS, a single 11-point numerical rating scale widely validated across different patient populations, where 0 represents no pain and 10 represents the worst possible pain. Data obtained through the NPRS are easy to document, intuitively interpretable and meet regulatory requirements for pain assessment and documentation. The NPRS has been shown to be reliable in assessing LBP intensity, also predicting the degree of disability in these patients. A change of 2 points on the NPRS has been considered to reflect the MCID in patients with LBP, indicating that any change equal to or greater than this value can be considered clinically relevant. However, the MCID has not yet been established in patients with LBRLP and neuropathic characteristics; therefore, a variation of 2 points will be used as a reference value, as in patients with LBP and those with chronic pain in general.

Secondary outcomes

  1. Disability

    Time frame: Baseline and 1 week post-intervention.

    Disability will be assessed using the Oswestry Disability Index (ODI), an instrument designed to evaluate the degree of disability associated with acute, subacute and chronic LBP. The ODI consists of a total of 10 items, one assessing pain and the remaining nine assessing activities of daily living, each rated on a 6-point ordinal scale ranging from the best to the worst scenario (0-5 points). The scores for each item will be summed to obtain a total between 0 and 50 points, with the following categories: no disability (0-4 points), mild disability (5-14 points), moderate disability (15-24 points), severe disability (25-34 points) and complete disability (35-50 points). The ODI has been shown to be reliable and valid for assessing disability in patients with LBP and has been validated in Spanish. The MCID varies across studies; in this case, the smallest reported value (a change of 5 points) will be used as the reference for significant changes.

  2. Health-related quality of life

    Time frame: Baseline and 1 week post-intervention.

    The SF-12 questionnaire, a shortened version of the SF-36, will be used for this assessment. The SF-12 consists of 12 items that evaluate eight different parameters: physical functioning, role limitations due to physical problems, bodily pain, general health, vitality, social functioning, role limitations due to emotional problems and mental health perception. The items are combined and transformed to provide both a physical and a mental health score, each ranging from 0 (worst) to 100 (best). The SF-12 has been shown to be valid and reliable in populations with chronic LBP. The MCID related to quality of life in patients with LBP has been established as improvements greater than 3.77 points in the mental component and 3.29 points in the physical component.

  3. Neuropathic component of pain

    Time frame: Baseline and 1 week post-intervention.

    This variable will be measured using the S-LANSS pain scale, a self-administered instrument designed to identify patients with pain of neuropathic characteristics. It is a simple scale consisting of seven items with binary responses (yes or no), relating to the presence of symptoms (five items) or clinical signs (two items). The maximum possible score is 24 points, with scores equal to or greater than 12 considered clear indicators of the presence of a neuropathic pain component. The S-LANSS scale has been shown to be reliable for diagnosing pain with neuropathic characteristics and has been validated in Spanish.

  4. Pressure pain threshold

    Time frame: Baseline, immediately after the intervention and 1 week post-intervention.

    To assess PPT a pressure algometer will be used, determining the minimum amount of pressure required for the patient to feel pain. PPT will be measured at three different points on each side: tibial nerve (posterior aspect of the knee), peroneal nerve (at the level of the fibular head), and the sciatic nerve trunk (gluteal region), repeating each measurement three times and averaging the results. According to the classification by Shrout and Fleiss, algometry measurement of PPT at the tibial nerve has shown good intra-rater reliability (ICC = 0.64) and acceptable inter-rater reliability (ICC = 0.56) in asymptomatic individuals. For the peroneal nerve, intra-rater reliability is excellent (ICC = 0.84) and inter-rater reliability is good (ICC = 0.70). For the sciatic nerve, intra-rater reliability is excellent (ICC = 0.90) and inter-rater reliability is good (ICC = 0.75).

  5. SLR test outcome

    Time frame: Baseline, immediately after the intervention and 1 week post-intervention.

    The test will be performed with the participant in a supine position, passively raising the lower limb by flexing the hip while keeping the knee extended. A recent meta-analysis has highlighted ongoing concerns regarding its reliability and diagnostic accuracy, suggesting that incorporating structural differentiation movements may improve its performance. Based on previous research of limited quality, the test has been reported to have high sensitivity and low specificity, although results vary between studies. Likelihood ratios also differ widely across investigations, with LR+ ranging from 1.07 to 4.73 and LR- from 0.27 to 0.96. It has been determined that diagnosing radicular pain and radiculopathy in patients with LBRLP, when based solely on history and physical examination, has only slight inter-rater reliability (Kappa 0.35). In terms of interpretation, the SLR test is considered positive when it elicits familiar symptoms that relieve upon returning to the starting position.

  6. Pain Descriptors: Familiar Symptomatology and Paresthesias

    Time frame: Baseline, immediately after the intervention and 1 week post-intervention.

    Categorical scales will be used to record the extent to which the SLR test reproduces symptomatology recognized by the patient as familiar (not familiar, slightly familiar, considerably familiar or exact reproduction of symptoms) and the severity of any dysesthesias or paresthesias experienced (none, mild-moderate or severe). This questionnaire has demonstrated moderate to excellent inter-rater reliability (ICC = 0.78-0.96).

  7. Range of motion in hip flexion

    Time frame: Baseline, immediately after the intervention and 1 week post-intervention.

    Data on the hip flexion ROM achieved during the SLR test will be collected. The participant will be in a supine position and the hip flexion movement will be recorded using anatomical reference points and assessed using Kinovea, a motion-analysis software. A previous study using this method reported excellent intra- and inter-rater reliability, with ICCs ranging from 0.985 to 0.999 and a minimal detectable change of 1.3-4° of hip flexion in patients with LBP. In contrast, a previous meta-analysis concluded that inter-rater reliability for ROM measurement during the SLR test is poor, with variations ranging from 13° to 20º.

  8. Sciatic nerve stiffness

    Time frame: Baseline, immediately after the intervention and 1 week post-intervention.

    An experienced ultrasound researcher will perform shear wave elastography (SWE) to assess sciatic nerve stiffness using a Logiq P9 XDclear™ system with convex (1-6 MHz) and linear (6-15 MHz) probes. Exams will be bilateral in the subgluteal fossa, with participants prone, ankle neutral, and knee extended. The nerve will be identified axially for thickness, width and area, then imaged longitudinally for SWE. Stable transducer positioning will allow simultaneous B-mode and SWE display. Stiffness will be expressed in kPa, taking at least three measurements that will be averaged for analysis. All images will be acquired by the same investigator. This method shows good reliability (ICC = 0.869), and higher stiffness (≈11.3%) has been observed in affected legs of patients with LBRLP compared to their unaffected side and to healthy controls.

  9. Global perceived improvement

    Time frame: Immediately after the intervention and 1 week post-intervention.

    Global perceived improvement will be measured using a 7-point Likert scale ranging from "much worse" to "much better." Clinical improvement will be considered in participants who report feeling "moderately better" or "much better".

  10. Adverse events

    Time frame: Through study completion, an average of 2 years.

    Adverse events will be defined as any problem related to the intervention that causes symptoms lasting at least two days or requiring specific treatment.

Other outcomes

  1. Sociodemographic variables

    Time frame: Baseline.

    Sociodemographic data will be collected using a standardized form in which participants will be required to provide their age, gender, occupation, height, weight, ethnicity, education level, comorbidities, history of sports activity, symptoms in other joints, duration of symptoms and medication use.

Sponsors and collaborators

Lead sponsor

Universidad Complutense de Madrid

Other

Collaborators

  • Colegio de Fisioterapeutas de la Comunidad de Madrid

Registry information

Important dates

Study start
2026
Primary completion
2026
Study completion
2027
First posted
Jan 29, 2026
Registry last updated
May 14, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.